Foster Dykema Cabot & Partners, LLC Crispr Therapeutics Ag Transaction History
Foster Dykema Cabot & Partners, LLC
- $1.12 Trillion
- Q2 2024
A detailed history of Foster Dykema Cabot & Partners, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Foster Dykema Cabot & Partners, LLC holds 10 shares of CRSP stock, worth $454. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10
Previous 10
-0.0%
Holding current value
$454
Previous $682,000
20.82%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
523Shares Held
58MCall Options Held
1.73MPut Options Held
1.84M-
Capital International Investors Los Angeles, CA7.87MShares$357 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.78MShares$353 Million3.82% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$143 Million0.13% of portfolio
-
Nikko Asset Management Americas, Inc.3.15MShares$143 Million1.99% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$126 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.54B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....